GLUE
Monte Rosa Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$23.48-4.40%
Price as of Jul 20, 2026
GLUE profitability
Monte Rosa Therapeutics, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 95.3%
- EBITDA margin
- -287.6%
- EBIT margin
- -345.2%
- Net margin
- -302.7%
- Free cash flow margin
- -45.8%
Returns
- Return on equity
- -24.9%
- Return on assets
- -17.7%
- Return on invested capital
- -26.4%
- Asset turnover
- 0.07x
Cash efficiency
- Cash from operations
- -$14.7M
- Cash per share
- $7.89
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.